Researchers find that influenza has an Achilles' heel

Flu epidemics cause up to half a million deaths worldwide each year, and emerging strains continually threaten to spread to humans and cause even deadlier pandemics. A study published by Cell Press on April 10 in the journal Immunity reveals that a drug that inhibits a molecule called prostaglandin E2 (PGE2) increases survival rates in mice infected with a lethal dose of the H1N1 flu virus. The findings pave the way for an urgently needed therapy that is highly effective against the flu virus and potentially other viral infections.

"Drugs that specifically target PGE2 pathways have already been developed and tested in animals, so our results have excellent potential for clinical translation, not only for the treatment of influenza, but also other that interact with similar host immune pathways," says senior study author Maziar Divangahi of McGill University.

Despite the worldwide use of vaccination and other antiviral interventions, the remains a persistent threat to human health. To investigate molecular pathways that could be targeted by novel interventions, Divangahi and his team became interested in ibuprofen, which is commonly used to manage flu-like symptoms. By inhibiting a molecule called cyclooxygenase (COX), ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) lower the production of prostaglandins—immune molecules that contribute to pain and fever. But COX inhibition has produced conflicting effects on immune responses and survival rates in animals infected with the flu virus, highlighting the importance of clarifying the role of prostaglandins in antiviral immunity.

In the new study, Divangahi and his team found that mice genetically engineered to lack PGE2 showed enhanced immune responses, lower viral levels in the lungs, and better survival rates following infection with a of the H1N1 flu virus compared with infected mice that were not genetically modified. Similarly, mice treated with a compound that inhibits PGE2 showed enhanced antiviral immunity and following infection with a lethal dose of the flu virus compared with untreated mice.

"We believe that previous studies produced conflicting results because COX inhibition affects all prostaglandins, not just PGE2," Divangahi says. "Our findings suggest that different prostaglandins have different roles in and that specific inhibition of PGE2 will be much more effective than NSAIDs at protecting against influenza infection."

More information: Immunity, Coulombe et al.: "Targeted Prostaglandin E2 Inhibition Enhances Anti-Viral Immunity through Induction of Type I Interferon and Apoptosis in Macrophages." dx.doi.org/10.1016/j.immuni.2014.02.013

add to favorites email to friend print save as pdf

Related Stories

Fatty acids could lead to flu drug

Mar 07, 2013

Flu viruses are a major cause of death and sickness around the world, and antiviral drugs currently do not protect the most seriously ill patients. A study published March 7th by Cell Press in the journal Cell reveals that a ...

The rocky road to a better flu vaccine

Jan 23, 2014

Currently approved flu vaccines are less effective in the elderly, yet an estimated 90% of influenza-related deaths occur in people over 65. A paper published on January 23rd in PLOS Pathogens reports on the ...

Recommended for you

Food allergies more widespread among inner-city children

Aug 14, 2014

Already known for their higher-than-usual risk of asthma and environmental allergies, young inner-city children appear to suffer disproportionately from food allergies as well, according to results of a study led by scientists ...

New weapon of the immune system discovered

Aug 14, 2014

Max Planck researchers have discovered a completely new way in which the immune system recognizes pathogens. The aryl hydrocarbon receptor has long been a focus of research for pharma-cologists and toxicologists, ...

User comments